"A New Convergence of Pharma and Biotech with Fashion Brands"
Targeting the Beauty and Healthcare Markets, Including Dermocosmetics

Ildong Pharmaceutical Group and Nine and Company are moving in earnest to tap the beauty and healthcare markets through their joint venture (JV), IDNINE.


Ildong Pharmaceutical said on October 27 that it held a launch ceremony for IDNINE the previous day at Nine and Company in Seongdong-gu, Seoul.


Key officials from both sides, including Ildong Pharmaceutical Co-CEO Yoon Woongseop (front row, second from left), Ildong Pharmaceutical Co-CEO Lee Jaejun (back row, third from left), Ildong Holdings CEO Choi Gyuhwan (back row, second from left), Nine&Company CEO Lee Giun (front row, second from right), ID9 Co-CEO nominee Shin Ajeong (front row, first from left), and ID9 Co-CEO nominee Jeong Mingyu (front row, first from right), attend the launch ceremony of their joint venture and pose for a commemorative photo. Ildong Pharmaceutical

Key officials from both sides, including Ildong Pharmaceutical Co-CEO Yoon Woongseop (front row, second from left), Ildong Pharmaceutical Co-CEO Lee Jaejun (back row, third from left), Ildong Holdings CEO Choi Gyuhwan (back row, second from left), Nine&Company CEO Lee Giun (front row, second from right), ID9 Co-CEO nominee Shin Ajeong (front row, first from left), and ID9 Co-CEO nominee Jeong Mingyu (front row, first from right), attend the launch ceremony of their joint venture and pose for a commemorative photo. Ildong Pharmaceutical

View original image

IDNINE plans to enter the beauty and healthcare markets, including dermocosmetics, by combining Ildong Pharmaceutical Group's accumulated research and development capabilities in probiotics and the microbiome with Nine and Company's experience in brand management and marketing.


IDNINE is positioning Seraglow, a microbiome-based probiotic cosmetic ingredient developed using Ildong Pharmaceutical Group's proprietary technology, as a key competitive advantage. Ildong Pharmaceutical Group has researched the potential use of around 20 active metabolites produced during the fermentation of probiotic strains in skincare. It has now established a basis for commercialization, including two patents related to Seraglow technology and two SCI-indexed research papers.



IDNINE plans to develop products specializing in skin barrier care using Seraglow and to roll out a range of high-performance dermocosmetic skincare products sequentially starting next year.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing